Thromboembolism - Pipeline Review, H2 2018

Thromboembolism - Pipeline Review, H2 2018


  • Products Id :- GMDHC10582IDB
  • |
  • Pages: 98
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Thromboembolism-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thromboembolism-Pipeline Review, H2 2018, provides an overview of the Thromboembolism (Cardiovascular) pipeline landscape.

When a blood clot (thrombus) breaks and travels in the blood, this is called a thromboembolism. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the chest wall or leg. Risk factors include hypertension, diabetes mellitus, cigarette smoking, and high cholesterol levels. Treatment includes anticoagulants, thrombolytic therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thromboembolism-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Thromboembolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thromboembolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Thromboembolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 3, 1, 5, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Thromboembolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Thromboembolism (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Thromboembolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Thromboembolism (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Thromboembolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Thromboembolism (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Thromboembolism (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Thromboembolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Thromboembolism-Overview

Thromboembolism-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Thromboembolism-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Thromboembolism-Companies Involved in Therapeutics Development

Bayer AG

China Biologic Products Inc

Daiichi Sankyo Co Ltd

F. Hoffmann-La Roche Ltd

GC Pharma

Ionis Pharmaceuticals Inc

Johnson & Johnson

Portola Pharmaceuticals Inc

Tetherex Pharmaceuticals Corp

Verseon Corp

Thromboembolism-Drug Profiles

antithrombin III (human)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-1213790-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

betrixaban-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

edoxaban tosylate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GCC-2107-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONIS-FXIRx-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-9375-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lysimab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Thromboembolism-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rivaroxaban-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SelK-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAP-ANV-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRX-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VE-1902-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VE-2851-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YG-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Thromboembolism-Dormant Projects

Thromboembolism-Discontinued Products

Thromboembolism-Product Development Milestones

Featured News & Press Releases

Jun 14, 2018: Verseon to Initiate Phase I Study to Evaluate a New Precision Oral Anticoagulant with Reduced Bleeding Risk

Jun 07, 2018: Verseon presents new data on its precision oral anticoagulants at BIO International Convention 2018

May 18, 2018: LIXIANA (edoxaban) Shows Reduced Rate of a Variety of Types of Intracranial Haemorrhage Compared to Warfarin in New Sub-analysis Presented at the European Stroke Organisation Conference 2018

Mar 23, 2018: Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban in the European Union

Feb 20, 2018: Portola Pharmaceuticals Announces Results of CHMP Oral Explanation for Betrixaban

Dec 19, 2017: FDA Approves Prior Approval Supplement for Commercial Launch of Portola Pharma's Novel Oral Anticoagulant Bevyxxa (betrixaban)

Dec 13, 2017: Once-Daily, Oral LIXIANA (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CANCER Study

Nov 30, 2017: Portola Pharmaceuticals to Present New Data on Betrixaban at the 59th American Society of Hematology (ASH) Annual Meeting

Nov 21, 2017: Portola Pharmaceuticals Provides Update on Bevyxxa (betrixaban) Commercial Launch

Nov 07, 2017: Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data on Betrixaban to be Presented at the America Heart Association Scientific Sessions 2017

Nov 01, 2017: Janssen to Present Abstracts on XARELTO at ASH 2017

Oct 30, 2017: Bayer receives FDA approval for Xarelto 10 mg once daily for the extended treatment of venous thromboembolism

Sep 15, 2017: Bayer receives positive CHMP opinion for rivaroxaban 10 mg once daily for the extended prevention of venous thromboembolism

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Thromboembolism, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

List of Tables

Number of Products under Development for Thromboembolism, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Thromboembolism-Pipeline by Bayer AG, H2 2018

Thromboembolism-Pipeline by China Biologic Products Inc, H2 2018

Thromboembolism-Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Thromboembolism-Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Thromboembolism-Pipeline by GC Pharma, H2 2018

Thromboembolism-Pipeline by Ionis Pharmaceuticals Inc, H2 2018

Thromboembolism-Pipeline by Johnson & Johnson, H2 2018

Thromboembolism-Pipeline by Portola Pharmaceuticals Inc, H2 2018

Thromboembolism-Pipeline by Tetherex Pharmaceuticals Corp, H2 2018

Thromboembolism-Pipeline by Verseon Corp, H2 2018

Thromboembolism-Dormant Projects, H2 2018

Thromboembolism-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Bayer AG

China Biologic Products Inc

Daiichi Sankyo Co Ltd

F. Hoffmann-La Roche Ltd

GC Pharma

Ionis Pharmaceuticals Inc

Johnson & Johnson

Portola Pharmaceuticals Inc

Tetherex Pharmaceuticals Corp

Verseon Corp

Thromboembolism Therapeutic Products under Development, Key Players in Thromboembolism Therapeutics, Thromboembolism Pipeline Overview, Thromboembolism Pipeline, Thromboembolism Pipeline Assessment

select a license
Single User License
USD 2000 INR 142720
Site License
USD 4000 INR 285440
Corporate User License
USD 6000 INR 428160

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com